Zobrazeno 1 - 10
of 42
pro vyhledávání: '"Adult Clinical Trials–Immunologic"'
Autor:
Robert O. Dillman, Thomas H. Taylor, Mohamad Alsharif, Candace Hsieh, Kong Xiao-Tang, Beverly Fu, Renato V. LaRocca, Robert Aiken, Christopher Duma, Gabriel Nistor, Daniela A. Bota, David Picconi
Publikováno v:
Neuro-oncology, vol 21, iss Suppl 6
Neuro Oncol
Neuro-Oncology, vol 21, iss Supplement_6
Neuro Oncol
Neuro-Oncology, vol 21, iss Supplement_6
Newly-diagnosed glioblastoma (GBM) patients have a limited survival (18–24 months). In the last decade immunotherapy has improved survival for patients with other malignancies, but not GBM. Herein we present the design and initial enrollment result
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::fe22ebef070ffea70f9cd6cea9975a2f
https://escholarship.org/uc/item/4m40r6bh
https://escholarship.org/uc/item/4m40r6bh
Autor:
Brittany Evernden, Robert J.B. Macaulay, Sepideh Mokhtari, John A. Arrington, Timothy J. Robinson, Michael Jaglal, Raju Raval, Solmaz Sahebjam, Nam D. Tran, Peter A. Forsyth, Michael Yu, Arnold B. Etame, Melissa Wicklund, Tyra Gatewood
Publikováno v:
Neuro Oncol
BACKGROUND There is strong pre-clinical evidence that combining CTLA4 and PD-1/PDL-1 blockade with antiangiogenic agents and HFSRT independently enhance anti-tumor immune responses and tumor regression. METHODS This phase I study includes a safety co
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4a893d80b3fe093ececc3d99cbcff003
https://europepmc.org/articles/PMC6847102/
https://europepmc.org/articles/PMC6847102/
Autor:
Sonisha Warren, Deborah Sampson, Maryam Rahman, Dongjiang Chen, Ashley Ghiaseddin, David Tran, Anne Allen, Valerie Greene, Nagheme Thomas
Publikováno v:
Neuro Oncol
BACKGROUND/OBJECTIVE Tumor treating Fields (TTFields) plus maintenance temozolomide is an approved standard treatment for newly diagnosed Glioblastoma (GBM). TTFields are alternating electric fields of low intensity and intermediate frequency deliver
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::66ee9064367974e58655b2a2067df1c0
https://europepmc.org/articles/PMC6847508/
https://europepmc.org/articles/PMC6847508/
Autor:
Nathan Demars, Yunxia Wang, Laurence J.N. Cooper, Amy Smith, John Miao, Ennio Antonio Chiocca, Arnold Gelb, Jill Buck, Sylvia Kurz, Rimas V. Lukas, John S. Yu, John Zhou, Ganesh Rao, Joseph Landolfi
Publikováno v:
Neuro Oncol
Ad-RTS-hIL-12 (Ad) is a novel gene therapy, conditionally expressing IL-12 via the RheoSwitch Therapeutic System® (RTS®) gene switch under control of an oral activator ligand, veledimex (V). We previously reported results from 51 subjects (NCT02026
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3ceb0131cf8d19db1b45fb83fa8e382e
https://europepmc.org/articles/PMC6847372/
https://europepmc.org/articles/PMC6847372/
Autor:
Brian J. Soher, Gordana Vlahovic, Eric S. Lipp, Hai Yan, James E. Herndon, Henry S. Friedman, Dina Randazzo, Margaret Johnson, Patrick Healy, John Sampson, Sarah Woodring, Denise Jaggers, Gary E. Archer, David M. Ashley, Kendra L. Congdon, Annick Desjardins, Allan H. Friedman, Katherine B. Peters
Publikováno v:
Neuro Oncol
BACKGROUND Low grade gliomas (LGGs) represent 10–15% of glial tumors in adults and while LGG patients have a better prognosis over high-grade gliomas, these cancers ultimately recur and transform to more aggressive tumors. Isocitrate dehydrogenase
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::85e039c8d1f62cfb3c174ed70c132e7a
https://europepmc.org/articles/PMC6847076/
https://europepmc.org/articles/PMC6847076/
Autor:
Johnny Duerinck, Gil Awada, Julia Katharina Schwarze, Ines Dufait, Stephanie Peeters, Laura Seynave, Anne-marie Van Binst, Hendrik Everaert, Alex Michotte, Anne Rogiers, Vera Van Velthoven, Bart Neyns
Publikováno v:
Neuro Oncol
INTRODUCTION Intravenous (iv) administration of PD-1 blocking mAb is largely ineffective for the treatment of recurrent glioblastoma (rGB). Combination of iv-ipilimumab (IPI) plus nivolumab (NIVO) is associated with a high incidence of irAE. Intracer
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::50952fea1738c1a1fab84ad9228fd096
https://europepmc.org/articles/PMC6847104/
https://europepmc.org/articles/PMC6847104/
Autor:
Darell D. Bigner, David M. Ashley, Frances McSherry, Michael C. Brown, Zhi Wei, John Sampson, James E. Herndon, Smita K. Nair, Gao Zhang, Henry S. Friedman, Katherine B. Peters, Yiping He, Hai Yan, Allan H. Friedman, Dani P. Bolognesi, Matthias Gromeier, Nike Beuabier, Dina Randazzo, Xiang Lin, Annick Desjardins, Roger E. McLendon
Publikováno v:
Neuro Oncol
BACKGROUND The live attenuated oral poliovirus vaccine was modified to contain a heterologous internal ribosomal entry site stemming from human rhinovirus type 2, creating PVSRIPO. PVSRIPO recognizes CD155, an oncofetal cell adhesion molecule and tum
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5652c5c31f6a0bb476d22ffa5a927914
https://europepmc.org/articles/PMC6847607/
https://europepmc.org/articles/PMC6847607/
Autor:
Naoki Kagawa, Shota Tanaka, Tomokazu Aoki, Ryo Nishikawa, Shigeru Yamaguchi, Yoshiki Arakawa, Kazuhiko Sugiyama, Toshihiko Wakabayashi
Publikováno v:
Neuro Oncol
BACKGROUND The anti-programmed cell death protein 1 (PD-1) immune checkpoint antibody, nivolumab, may be beneficial in patients with recurrent glioblastoma. OBJECTIVE This open-label, non-comparative study assessed the efficacy and safety of nivoluma
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3ab3f0a143b34fcc54d892207a8b0589
https://europepmc.org/articles/PMC6847716/
https://europepmc.org/articles/PMC6847716/
Publikováno v:
Neuro Oncol
Patients with glioblastoma (GBM) have a median survival of 15 months despite aggressive treatment. Immunotherapies such as dendritic cell (DC) vaccines have modest clinical efficacy in small clinical trials. Treatment-related pseudo-progression confo
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::32f60bb2fc82f2a4ddbb722ca8210d07
https://europepmc.org/articles/PMC6846938/
https://europepmc.org/articles/PMC6846938/
Autor:
Yasuhiko Hattori, Nobushige Tsuboi, Yusuke Tomita, Kentaro Fujii, Isao Date, Keigo Makino, Hiroyuki Michiue, Yosuke Shimazu, Yuji Matsumoto, Tetsuo Oka, Kazuhiko Kurozumi, Atsuhito Uneda, Hiromi Kumorn, Keisuke Kaneda
Publikováno v:
Neuro Oncol
INTRODUCTION Expression of the gene encoding reduced expression in immortalized cells/Dickkopf-3 (REIC/Dkk-3) was reported to be reduced in a variety of human cancer cells. We previously examined the antitumor effect of an adenoviral vector carrying
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::eba712bb59d7d08d62d33c91e0b0ec7e
https://europepmc.org/articles/PMC6847855/
https://europepmc.org/articles/PMC6847855/